CAR-T cell therapy for hard-to-treat lupus
Part of Immune system & allergy, Skin clinical trials.
This trial tests a new immune cell therapy (CAR-T) for people with lupus that hasn't gotten better with standard treatments. The goal is to see if these modified cells can calm the overactive immune system and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed lupus diagnosis based on standard criteria.
- Your lupus should be active (moderate to severe symptoms) and not well controlled.
- You must have tried at least two prior lupus treatments, including certain medications like mycophenolate mofetil or cyclophosphamide, or had side effects from them.
- You must be 18 years or older and agree to follow the treatment plan.
- You must be in generally good health aside from lupus, with no major organ failure or active infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CAR-T cells) for people with lupus that has not responded well to standard treatments. It aims to reset the immune system to reduce lupus activity.
This early-phase study tests a special immune therapy (CAR-T cells) made to target disease-driving immune cells in adults with lupus that has not improved despite standard treatments. It may offer a new option for people with severe, active lupus symptoms.
This trial tests a new type of cell therapy called CAR-T cells that target a protein called CD70 on immune cells. The goal is to see if it can help people with active lupus that has not improved with standard treatments.
This trial tests whether a type of immune cell therapy called CAR-T can help people with active lupus that hasn't responded well to standard treatments. It aims to reduce disease activity and improve symptoms.
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins on immune cells (CD19 and BCMA) to treat lupus that hasn't responded to standard treatments. It may help people with moderate to severe lupus by reducing disease activity without ongoing medication.
This trial tests an experimental CAR-T cell therapy (IC19) for people with systemic lupus erythematosus (SLE) that hasn't gotten better after standard treatments. The goal is to see if this therapy can safely reduce lupus disease activity.
Hear when a new System Lupus Erythematosus(SLE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.